Cizzle Biotechnology Holdings PLC (CIZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) has a cash flow conversion efficiency ratio of 1.199x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-331.00K ≈ $-40.27 USD) by net assets (GBX-276.00K ≈ $-33.58 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cizzle Biotechnology Holdings PLC - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Cizzle Biotechnology Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cizzle Biotechnology Holdings PLC debt and liabilities for a breakdown of total debt and financial obligations.
Cizzle Biotechnology Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cizzle Biotechnology Holdings PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IMC Exploration Group Public Limited Company
LSE:IMC
|
-0.458x |
|
VOLATUS CAPITAL CORP.
F:VOY0
|
N/A |
|
Angus Energy PLC
LSE:ANGS
|
0.034x |
|
Cadogan Petroleum plc
LSE:CAD
|
-0.008x |
|
Quantum Helium Limited
LSE:QHE
|
-0.096x |
|
Arcontech Group Plc
LSE:ARC
|
0.113x |
|
PowerHouse Energy Group Plc
LSE:PHE
|
-0.190x |
|
Sumo Resources PLC
PA:MLSUM
|
N/A |
Annual Cash Flow Conversion Efficiency for Cizzle Biotechnology Holdings PLC (2006–2024)
The table below shows the annual cash flow conversion efficiency of Cizzle Biotechnology Holdings PLC from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Cizzle Biotechnology Holdings PLC (CIZ) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX82.00K ≈ $9.98 |
GBX-358.00K ≈ $-43.56 |
-4.366x | -929.63% |
| 2023-12-31 | GBX1.51 Million ≈ $183.36 |
GBX-639.00K ≈ $-77.75 |
-0.424x | -28.37% |
| 2022-12-31 | GBX2.64 Million ≈ $321.21 |
GBX-872.00K ≈ $-106.10 |
-0.330x | +69.33% |
| 2021-12-31 | GBX937.00K ≈ $114.01 |
GBX-1.01 Million ≈ $-122.77 |
-1.077x | +88.28% |
| 2020-12-31 | GBX32.00K ≈ $3.89 |
GBX-294.00K ≈ $-35.77 |
-9.188x | -761.46% |
| 2019-12-31 | GBX6.63K ≈ $0.81 |
GBX-7.07K ≈ $-0.86 |
-1.067x | -148.86% |
| 2018-12-31 | GBX-235.00K ≈ $-28.59 |
GBX-513.00K ≈ $-62.42 |
2.183x | +951.36% |
| 2017-12-31 | GBX741.00K ≈ $90.16 |
GBX-190.00K ≈ $-23.12 |
-0.256x | -401.49% |
| 2016-12-31 | GBX2.19 Million ≈ $266.09 |
GBX186.00K ≈ $22.63 |
0.085x | +135.88% |
| 2015-12-31 | GBX2.40 Million ≈ $292.62 |
GBX-570.00K ≈ $-69.35 |
-0.237x | -127.41% |
| 2014-12-31 | GBX5.05 Million ≈ $614.07 |
GBX-526.00K ≈ $-64.00 |
-0.104x | +34.38% |
| 2013-12-31 | GBX4.27 Million ≈ $519.41 |
GBX-678.00K ≈ $-82.49 |
-0.159x | -424.98% |
| 2012-12-31 | GBX4.79 Million ≈ $583.17 |
GBX-145.00K ≈ $-17.64 |
-0.030x | +91.82% |
| 2011-12-31 | GBX4.08 Million ≈ $496.90 |
GBX-1.51 Million ≈ $-183.72 |
-0.370x | -329.38% |
| 2010-12-31 | GBX3.54 Million ≈ $430.96 |
GBX-305.00K ≈ $-37.11 |
-0.086x | +70.09% |
| 2009-12-31 | GBX521.00K ≈ $63.39 |
GBX-150.00K ≈ $-18.25 |
-0.288x | +69.03% |
| 2008-12-31 | GBX1.67 Million ≈ $202.70 |
GBX-1.55 Million ≈ $-188.47 |
-0.930x | -6.47% |
| 2007-12-31 | GBX2.40 Million ≈ $291.89 |
GBX-2.10 Million ≈ $-254.90 |
-0.873x | -104.62% |
| 2006-12-31 | GBX-58.00K ≈ $-7.06 |
GBX-1.10 Million ≈ $-133.47 |
18.914x | -- |
About Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more